ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1180

Deficiency and Altered Phenotype of Mucosal-associated Invariant T Cells in Systemic Sclerosis

Manon Lesturgie-Talarek1, Virginie Gonzalez1, Camelia Frantz2, Noémie Sénot1, Zouriatou Gouda1, Camille Rousseau1, Lucie Beaudoin1, Agnès Lehuen1, Jérôme Avouac3 and Yannick Allanore4, 1INSERM U1016, Institut Cochin, Paris, France, 2Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 3University of Paris, Paris, France, 4Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

Meeting: ACR Convergence 2022

Keywords: immunology, interstitial lung disease, Systemic sclerosis, T Cell, T-Lymphocyte

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs such as the lung. Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes able to produce various cytokines and cytotoxic mediators such as granzyme B. Decreased level and altered phenotype of MAIT cell have been shown in various autoimmune disease. Moreover, some data support a potential role in fibrotic disorders as highlighted in liver fibrosis. Therefore, we herein addressed the question as whether MAIT cells may have an altered profile in systemic sclerosis.

Our objective was to determine the implication of MAIT cells in SSc.

Methods: MAIT cell frequency was analyzed by flow cytometry, using fresh peripheral blood from 74 consecutive SSc patients compared to 44 healthy donors. In addition, in depth MAIT cell phenotype and function were analyzed using fresh peripheral blood from 29 women with SSc compared to 23 healthy women donors.

Results: Most of the healthy donors were female (95%) and the mean age was 45.6 years. Among the 74 SSc patients (89% were female, mean age: 57 years), the mean disease duration was 9 years, 42% had diffuse cutaneous SSc and 48% had an interstitial lung disease (ILD). Proportion of circulating MAIT cell frequency was significantly reduced by 55% in SSc compared to healthy donors (1.4 % vs. 3.1%, p< 0.0001) (Figure 1A). We next investigated whether MAIT cell frequency was associated with clinical variables in SSc patients. MAIT cell frequency was significantly reduced in patients with interstitial lung disease (SSc-ILD) (0.49% vs. 0.91% in patients without ILD, p=0.027) (Figure 1B) even lower in the patients with severe ILD and reduced forced vital capacity (FVC) (0.25% in patients with FVC < 75% vs. 0.94% in patients with FVC >75%). Deficiency of MAIT cells did not correlate with disease activity score, type of SSc (diffuse or limited), systemic inflammation, and current immunosuppressive therapy.

In SSc patients, MAIT cells displayed a strongly activated phenotype indicated by markedly increased CD69+ MAIT cell frequency compared to healthy donors (p=0.0015, Figure 2A). Decreased proportion of MAIT expressing the anti-apoptotic marker Bcl2 was also observed. Regarding the cytokine profile analysis, no difference was observed compared to healthy controls (Figure 2A). Interestingly, MAIT cells from SSc-ILD patients had a more pronounced altered phenotype compared to SSc without ILD, with a correlation between MAIT expressing CCR6+ and MAIT frequency and a decreased production of IFN-γ (Figure 2B).

Conclusion: Circulating MAIT cells were reduced and exhibited an activated and pro-apoptotic phenotype in SSc patients compared to healthy controls. This peripheral MAIT cell deficiency may be related to enhanced apoptosis and/or homing in inflamed tissue, in particular the lung in SSc-ILD patients. Indeed, peripheral MAIT decrease was even more pronounced in SSc-ILD patients, and correlated with the expression of the tissue-recruitment chemokine CCR6. MAIT cells study in lung tissue as well as functional studies are necessary to better understand the implication of MAIT cells in systemic sclerosis.

Supporting image 1

MAIT cell frequency. (A) MAIT cell frequency in SSc (n=74) compared to healthy donors (n=44). (B) MAIT cell frequency in SSc with ILD (n=24) compared to SSc without ILD (n=50). ILD: interstitial lung disease. SSc: systemic sclerosis. Test: Mann-Whitney. **** p<0.0001.

Supporting image 2

Phenotype and function analysis of MAIT cells. The phenotype analysis included the study of activation (CD69, CD25, CD27), exhaustion (PD1, Tim3), recruitment (CD56, CCR6), survival (Bcl2, CD127) and proliferation (Ki67). The function analysis included the study of granzyme B (GzB) and cytokines (IFN, IL2, IL4, IL10, IL17, TNF) secretion. (A) Phenotype and function analysis of MAIT cells in SSc compared to controls. Circular bar plot represents negative logarithmic p values of MAIT cell phenotype and function differences between SSc (n=29) and healthy donors (n = 23). Red dashed circles represent p values. (B) Phenotype and function analysis of MAIT cells in SSc with ILD compared to SSc without ILD. Circular bar plot represents negative logarithmic p values of MAIT cell phenotype and function differences between SSc with ILD (n=24) and SSc without ILD (n=50). Red dashed circles represent p values.
Test: Mann-Whitney. * p ≤ 0, 05, ** p ≤ 0, 01, *** p ≤ 0, 001. SSc: Systemic Sclerosis. ILD: Interstitial Lung Disease . Bcl: B-cell lymphoma. CD: Cluster de Différentiation. CCR: C-C Motif Chemokine Receptor. IFN: Interferon. IL: Interleukine. GzB: Granzyme B. PD1: Programmed cell Death protein 1. TNF: Tumor Necrosis Factor.


Disclosures: M. Lesturgie-Talarek, None; V. Gonzalez, None; C. Frantz, None; N. Sénot, None; Z. Gouda, None; C. Rousseau, None; L. Beaudoin, None; A. Lehuen, None; J. Avouac, Galapagos, AbbVie, Lilly, Pfizer, Bristol Myers Squibb, Novartis, Fresenius-Kabi, Sanofi, Sandoz, Nordic Pharma, Biogen, Medac, Janssen, Roche-Chugai; Y. Allanore, Boehringer Ingelheim, Sanofi, Janssen, AbbVie/Abbott, Menarini, Curzion, Medsenic, Prometheus, AstraZeneca.

To cite this abstract in AMA style:

Lesturgie-Talarek M, Gonzalez V, Frantz C, Sénot N, Gouda Z, Rousseau C, Beaudoin L, Lehuen A, Avouac J, Allanore Y. Deficiency and Altered Phenotype of Mucosal-associated Invariant T Cells in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/deficiency-and-altered-phenotype-of-mucosal-associated-invariant-t-cells-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deficiency-and-altered-phenotype-of-mucosal-associated-invariant-t-cells-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology